Longevity & Aging · Metabolic & Cardiometabolic
testosterone therapy improves glycemic control
In plain terms: Does testosterone therapy help blood sugar or diabetes?
Part of: 💊 Testosterone therapy (TRT)
It's contested. One major trial (T4DM) found testosterone plus lifestyle changes reduced progression to diabetes, but that study used men with only mildly low testosterone plus a lifestyle program — and other solid trials found no blood-sugar benefit. Guidelines advise against using testosterone purely to treat diabetes.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
TRT's effect on blood sugar and insulin resistance is contested. The landmark T4DM trial found testosterone plus a lifestyle program cut progression to type 2 diabetes — an impressive result — and one meta-analysis reports improved HbA1c and HOMA-IR. But other well-run RCTs (Grossmann, Magnussen) and the large TestES individual-patient meta-analysis found no meaningful glycemic benefit.
The evidence (10)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Grossmann M et al. 2015 · Clin Endocrinol (Oxf) | meta-analysis | mixed | moderate | SR/meta 7 RCTs: modest HOMA1 improvement, non-significant HOMA2; no HbA1c or symptom-score benefit; does not support routine use. |
| Magnussen LV et al. 2016 · Diabetes Obes Metab | RCT | contradicts | moderate | RCT (aging T2DM): TRT did NOT improve insulin resistance or glycemic control; improved lean mass but reduced HDL. |
| Kapoor D et al. 2007 · Eur J Endocrinol | RCT | mixed | low | Crossover RCT (n=20): reduced leptin/waist; no significant effect on inflammatory markers (CRP, IL-6, TNF). |
| Griffith A et al 2025 · study_type: observational | observational | mixed | low | Single 52-year-old male on TRT for age-related testosterone decline had HbA1c fall from 7.2% to 5.9% at 3 months. Effect is confounded: co-delivered with enhanced lifestyle intervention and a 5-strain probiotic plus other supplements, so te |
| Hackett G et al. 2014 · J Sex Med | RCT | supports | moderate | BLAST RCT (T2DM): significantly reduced HbA1c, waist, weight; effect blunted in men with comorbid depression. |
| Wittert G et al. 2021 · Lancet Diabetes Endocrinol | RCT | supports | high | T4DM (n=1007): TRT + lifestyle cut 2-yr progression to T2DM vs lifestyle alone (RR 0.59); greater 2-h OGTT glucose reduction. |
| Majumdar A et al. 2021 · Diabetes Metab Syndr | mechanism | contradicts | low | IDEA consensus: recommends AGAINST TRT in T2DM men with only borderline-low T and no true hypogonadism. |
| Cruickshank M et al. 2024 · Nat Med | meta-analysis | contradicts | high | IPD meta 35 trials: no adverse glycemic effect but no meaningful glycemic improvement across trials overall. |
| Rastrelli G et al. 2018 · Sex Med Rev | mechanism | supports | low | Review: low T predicts incident metabolic syndrome and vice versa; T improves some components but authors flag 'not conclusive'. |
| Li SY et al. 2020 · Endocr J | meta-analysis | supports | moderate | Meta 18 RCTs (n=1415): reduced HbA1c (MD -0.67) and HOMA-IR (SMD -1.94); reduced LDL, triglycerides, weight, waist. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.